BioTelemetry, Inc. (NASDAQ:BEAT), announced today it has completed its acquisition of LifeWatch AG (SIX:LIFE). “We are gratified that LifeWatch AG shareholders embraced the immense strategic value and potential of this acquisition and moved quickly to support the BioTelemetry tender,” said Joseph H. Capper, President and Chief Executive Officer of BioTelemetry, Inc.Jul 12, 2017
The Research Division of BioTelemetry
BioTelemetry Research is an industry leader in clinical trials testing services, monitoring, data, and scientific consulting. Our comprehensive offerings provide global clients with world-leading technology, data management, and consulting services, streamlining the clinical trials process, and ensuring optimal research performance.
Every day, BioTelemetry Research’s global clinical trials services team meets the demands of Phase I–IV studies for the world’s largest pharmaceutical organizations, specialty pharmaceutical firms, emerging biotechnology companies, and medical device manufacturers. Providing a full range of centralized clinical trials testing modalities for both safety and endpoint evaluation, our core offerings include:
Comprehensive Testing Services for Clinical Trials
Today as BioTelemetry Research, we are a member of the world’s largest cardiac data network — processing over 2 billion heartbeats a day, while supporting more than 20,000 sites and 30,000 devices monthly, as well as monitoring over 600,000 patients and subjects a year. In addition to industry-leading global cardiovascular monitoring, we provide advanced imaging services for oncology, cardiovascular, metabolic diseases, neurologic, musculoskeletal imaging.
Boston, MA - Booth #72
Join BioTelemetry Research experts to learn how to better manage vendor contracts and overcome challenges you may face during your clinical trial.Sep 6-7, 2017
Publications / White Papers
Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatisis (NASH) are emerging as the most prevalent causes of liver disease in Western countries…
Join Richard Ehman, MD from the Mayo Clinic and BioTelemetry Research’s Jonathan Riek, PhD, VP, Musculoskeletal and Metabolic Imaging as they discuss non-invasive ways to assess NASH using imaging, including proton density fat fraction (PDFF), T1 relaxometry, magnetic resonance elastography (MRE), and the latest advances in MRE.